Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

Experts highlight the complex mix of genetics, biology and environment in obesity. Study shows fat cells' memory affects ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.  Fair Health ...